tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Boston Scientific (BSX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACADIA Pharmaceuticals (ACADResearch Report) and Boston Scientific (BSXResearch Report).

ACADIA Pharmaceuticals (ACAD)

In a report released today, Ami Fadia from Needham maintained a Hold rating on ACADIA Pharmaceuticals. The company’s shares closed last Wednesday at $19.29.

According to TipRanks.com, Fadia is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.4% and a 38.1% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and Avadel Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $28.64 average price target, representing a 64.7% upside. In a report released today, Stifel Nicolaus also maintained a Hold rating on the stock with a $20.00 price target.

See the top stocks recommended by analysts >>

Boston Scientific (BSX)

BTIG analyst Marie Thibault reiterated a Buy rating on Boston Scientific today and set a price target of $52.00. The company’s shares closed last Wednesday at $36.30, close to its 52-week low of $35.09.

According to TipRanks.com, Thibault is a 4-star analyst with an average return of 4.8% and a 25.5% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.

Boston Scientific has an analyst consensus of Strong Buy, with a price target consensus of $49.67, representing a 37.6% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $50.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACAD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed